HAL vs LCTX · P/E 9.3, $19.05B cap vs rev $9.5M
Halliburton Company (HAL) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
Halliburton Company (HAL) is a oil & gas equipment & services company listed on US.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
HAL does not have a complete income-statement cache yet.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
HAL currently screens at market cap $19.05B and trailing P/E 9.3. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the HAL and LCTX stock pages for the full models.
Not investment advice.